Fig. 2: Water fall plot.
From: A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors
Among the 39 evaluable patients with evaluable data, the Overall Response Rate (ORR) by RECIST 1.1 was 23%. Lower and upper dashed lines represent the cut-off for progressive disease (an increase of at least 20% in the sum of diameters of target lesions) and for partial response (at least 30% decrease), respectively. Partial response (blue); Stable disease (yellow) and Progression (purple). Source data are provided as a Source Data file.
